LogicBio Therapeutics (LogicBio Therapeutics) 6-1 Month Momentum % : 376.63% (As of Apr. 26, 2024)

View and export this data going back to 2018. Start your Free Trial

What is LogicBio Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-26), LogicBio Therapeutics's 6-1 Month Momentum % is 376.63%.

The industry rank for LogicBio Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

LOGC's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: 4.08 vs LOGC: 376.63

Competitive Comparison of LogicBio Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, LogicBio Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LogicBio Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LogicBio Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where LogicBio Therapeutics's 6-1 Month Momentum % falls into.

LogicBio Therapeutics (NAS:LOGC) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LogicBio Therapeutics (NAS:LOGC) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

LogicBio Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of LogicBio Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

LogicBio Therapeutics (LogicBio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LogicBio Therapeutics Inc (NAS:LOGC) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, 2nd Floor, Lexington, MA, USA, 02421

Website

https://www.logicbio.com

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.

Executives

Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Mariana Nacht	officer: Chief Scientific Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Daniel Gruskin	officer: Chief Medical Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Susan Kahn	director	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Joshua Blacher	officer: Interim CFO	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Andrea Paul	officer: General Counsel and Secretary	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Frederic Chereau	director, officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Kyle Chiang	officer: Chief Operating Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jonathan Quick	officer: Senior Director-Finance	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Erez Chimovits	director	P.O. BOX 4023, HERZLIYA PITUACH L3 4614001
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022